RecruitingPhase 4

Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)

Hong Kong2,000 participantsStarted 2018-12-01

Plain-language summary

To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. HBsAg positive, HBeAg negative, antibody to HBeAg-positive;
✓. Stable administration of anti-HBV neucleos(t)ides analogue mono therapy for at least more than one and a half year;
✓. Demonstration of undetectable HBV DNA on three occasions, each at least 6 months apart, which is consistent with the APASL stopping rule;
✓. Patients read, understand the consent form, and signed the study consent.

Exclusion criteria

✕. Patient with other liver diseases;
✕. Patient with concurrent hepatitis viruses or HIV infection;
✕. Patients are reluctant to stop their anti-HBV treatment.

What they're measuring

Incidence of HBsAg clearance

Timeframe: From baseline to the end of the fifth year after cessation of anti-HBV treatment.

Trial details

NCT IDNCT03792919

SponsorHumanity & Health Medical Group Limited

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-31

Contact for this trial

George Lau, MD

852-28613777 gkklau@netvigator.com

View on ClinicalTrials.gov More Chronic Hepatitis B trials